Persistent genotype-specific HPV infection increase the risk of cervical disease2,5
Cumulative proportion of ≥CIN2 among women with genotype-specific HPV persistence*5
Adapted from Elfgren et al. Am J Obstet Gynecol. 2017;216:264.e1-7.
*12,527 women aged 32-38 years with follow up of 195 women attending colposcopy who were cytologically normal but persistently HPV positive for at least 1 year.
MONITORING GENOTYPE-SPECIFIC HPV PERSISTENCE IS KEY TO IDENTIFYING YOUR PATIENTS AT MOST RISK FOR DEVELOPING CERVICAL DISEASE.1,2,5
Extended genotyping helps track genotype-specific HPV persistence
HPV infection history and current HPV results are both critical when assessing the risk for cervical cancer and guiding patient management.1
The BD Onclarity™ HPV Assay is the only FDA-approved assay that helps track genotype-specific HPV persistence using extended genotyping3,4
Learn more The value of extended genotyping
- CIN, cervical intraepithelial neoplasia;
- CIN2, cervical intraepithelial neoplasia grade 2;
- FDA, Food and Drug Administration;
- HPV, human papillomavirus;
- hrHPV, high-risk human papillomavirus.
- Perkins RB et al. J Low Genit Tract Dis. 2020;24:102-131.
- Bodily J et al. Trends Microbiol. 2011;19(1):33-39.
- BD Onclarity™ HPV Assay European Product information, 8089899(14). Updated November 2020.
- BD Press Release. BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities. July 22, 2020.
- Elfgren K et al. Am J Obstet Gynecol. 2017;216(3):264.e1-7.